Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Silver nitrate 75% caustic applicators
1307000Q0AAACAC
|
Silver nitrate | Silver nitrate | Skin | 319 |
|
Beclometasone 0.025% cream
1304000C0AAAAAA
|
Beclometasone dipropionate (Topical) | Beclometasone dipropionate | Skin | 316 |
|
Verrugon complete 50% ointment
1307000M0BFAAAE
|
Verrugon | Salicylic acid | Skin | 316 |
|
Chlorhexidine gluconate 1% solution
1311020L0AAANAN
|
Chlorhexidine gluconate (Topical cleanser) | Chlorhexidine gluconate | Skin | 314 |
|
Covermark finishing powder
130802000BBAHA0
|
Proprietary compound preparation BNF 1308020 | Other camouflage preparations | Skin | 313 |
|
Nizoral Dandruff 2% shampoo
1309000I0BBABAA
|
Nizoral (Scalp) | Ketoconazole | Skin | 306 |
|
Povidone-Iodine 10% antiseptic solution
1311040K0AAATAT
|
Povidone-Iodine (Topical Disinfectant/Cleanser) | Iodine compounds | Skin | 303 |
|
Dexpanthenol 5% ointment
1302010E0AAACAC
|
Dexpanthenol (Topical) | Dexpanthenol | Skin | 302 |
|
Diprosone 0.05% lotion
1304000D0BBAEBC
|
Diprosone | Betamethasone esters | Skin | 301 |
|
Cepton 1% medicated skin wash
1311020L0BKAAAN
|
Cepton (Topical cleanser) | Chlorhexidine gluconate | Skin | 300 |
|
Mycota cream
1310020Z0BCAAAD
|
Mycota | Undecenoates | Skin | 300 |
|
Quinoderm facewash
1311020L0CFAABN
|
Quinoderm (Topical Chlorhexidine) | Chlorhexidine gluconate | Skin | 299 |
|
Metrosa 0.75% gel
1310012K0BKAAAR
|
Metrosa | Metronidazole | Skin | 296 |
|
Mildison Lipocream 1% cream
1304000V0BQAAAD
|
Mildison Lipocream | Hydrocortisone | Skin | 294 |
|
Dimeticone 10% / Cetrimide 0.3% cream
1302020D0AAAEAE
|
Dimeticone (Barrier) | Dimeticone (Barrier) | Skin | 286 |
|
Mepyramine 2% cream
1303000M0AAAAAA
|
Mepyramine (Topical) | Mepyramine maleate | Skin | 275 |
|
Uvistat lipscreen SPF 50
130801000BBNQA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 269 |
|
Coal tar 6% cream
1305020C0AABCBC
|
Coal tar/tar (Topical) | Tars | Skin | 267 |
|
Fluticasone 0.005% ointment
1304000S0AAABAB
|
Fluticasone propionate (Topical) | Fluticasone propionate (Topical) | Skin | 264 |
|
Chlorhexidine gluconate 1% cream
1311020L0AAAFAF
|
Chlorhexidine gluconate (Topical cleanser) | Chlorhexidine gluconate | Skin | 258 |
|
Xepin 5% cream
1303000F0BCAAAA
|
Xepin | Doxepin hydrochloride | Skin | 255 |
|
Urea 5% scalp application
1302010U0AAAWAW
|
Urea (Emollient) | Urea | Skin | 248 |
|
Aveeno Intense Relief hand cream
130201000BBKXA0
|
Proprietary compound emollients | Other emollient preparations | Skin | 247 |
|
Tacalcitol 4micrograms/g lotion
1305020R0AAABAB
|
Tacalcitol | Tacalcitol | Skin | 246 |
|
Sunsense sensitive cream SPF 50+
130801000BBPTA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 245 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.